JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, comparative success has not been attained, as cells containing the JAK2-activating mutation persist in patients undergoing JAK2 inhibitor therapy, and unlike imatinib in CML, JAK2 inhibitors do not induce remission.